Plain-English translation of NCT06775340 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase 2 clinical trial testing a new medication called RSS0343 to see if it can safely treat bronchiectasis—a condition where parts of your lungs become damaged and don't clear mucus properly. Researchers want to understand how well this tablet works, how your body handles it, and whether it causes any side effects.
Bronchiectasis can cause chronic coughing, breathing problems, and frequent infections because the damaged airways trap mucus and bacteria. Currently, treatment options are limited, so this trial is exploring whether this medication could offer patients a new way to manage their condition.
You likely qualify if…
You likely don't qualify if…
You would take RSS0343 tablets as directed while researchers monitor your health through regular visits and tests to measure how the medication affects your lungs and overall well-being. The study will track your symptoms, check your lung function, and watch for any side effects over the course of the trial. You'll need to avoid certain medications and infections during participation and keep detailed records of how you're doing.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Enrollment target
~252 participants
Started
January 2025
Primary completion
November 2027
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Zi Lin
Jiangsu HengRui Medicine Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.